- Boeing to raise up to $25 bn as strike weighs on finances
- Oil prices fall on easing Middle East fears
- Boeing announces intention to raise up to $25 bn
- Ferguson to leave Man Utd ambassador role as club cuts costs
- Oil prices tumble on easing Middle East fears
- Oil prices hit by easing Middle East fears, most Asian markets rise
- Hopes pinned on peace across Taiwan Strait after drills
- Belgian pathologist and literary star gives 'voice to the dead'
- East Timor fights new battles 25 years after independence vote
- Oil prices drop on easing fears over Middle East, most markets rise
- Reoxygenating oceans: startups lead the way in Baltic Sea
- King Charles III heads to Australia and Commonwealth meeting
- Wall Street stocks hit fresh records as oil prices slide
- Strike-hit Boeing leaves experts puzzled by strategy
- NASA launches probe to study if life possible on icy Jupiter moon
- EVs seek to regain sales momentum at Paris Motor Show
- NASA probe Europa Clipper lifts off for Jupiter's icy moon
- 'Unsustainable' housing crisis bedevils Spain's socialist govt
- Stocks shrug off China disappointment but oil slides
- Stocks diverge, oil retreats as China disappoints markets
- Trio wins economics Nobel for work on wealth inequality
- Ex-Stasi officer jailed over 1974 Berlin border killing
- Shanghai stocks gain after stimulus briefing as markets rally
- Shanghai stocks gain after stimulus briefing as Asian markets rally
- Nearly 90, but opera legend Kabaivanska is still calling tune
- With inflation down, ECB eyes faster tempo of rate cuts
- Is life possible on a Jupiter moon? NASA goes to investigate
- Ex-Stasi officer faces verdict over 1974 Berlin border killing
- Role of government, poverty research tipped for economics Nobel
- In milestone, SpaceX 'catches' megarocket booster after test flight
- In a first, SpaceX 'catches' megarocket booster after test flight
- Bangladeshi Hindus shrug off attack worries to celebrate festival
- Ubisoft fears assassin's hit over falling sales
- Vietnam, China hold talks on calming South China Sea tensions
- SpaceX will try to 'catch' giant Starship rocket shortly before landing
- Japan's former empress Michiko discharged after surgery: reports
- Japan's former empress Michiko discharged after surgey: reports
- 'Little Gregory' murder haunts France 40 years on
- Tariffs, tax cuts, energy: What is in Trump's economic plan?
- Amazon wants to be everything to everyone
- Jewish school in Canada hit by gunfire for second time
- With medical report Harris seeks to play health card against Trump
- China-EU EV tariff talks in Brussels end with 'major differences': Beijing
- Buried Nazi past haunts Athens on liberation anniversary
- Harris to release medical report confirming fitness for presidency: campaign
- Nobel prize a timely reminder, Hiroshima locals say
- China offers $325 bn in fiscal stimulus for ailing economy
- Small Quebec company dominates one part of NHL hockey: jerseys
- Boeing to cut 10% of workforce as it sees big Q3 loss
- Want to film in Paris? No sexism allowed
Novartis upgrades outlook despite US legal setback
Swiss pharmaceutical giant Novartis raised its earnings guidance for the second time this year on Tuesday despite a legal setback in the United States and announced it will spin off its generics unit later this year.
The company, which is focusing on its core pharmaceutical operations, said it plans to spin off its Sandoz generics unit at the beginning of the fourth quarter by listing its shares on the SIX Swiss stock exchange.
After the spinoff, Novartis will focus on five core therapeutic areas: cardiovascular, immunology, neuroscience, solid tumours and haematology.
During the second quarter, Novartis saw its net profits jump by 54 percent from the same period last year to $2.3 billion thanks to both rising sales and lower restructuring charges.
Sales rose by 9 percent during the April-June period to $13.6 billion, beating the analyst consensus of $13.2 billion established by Swiss financial news service AWP.
The pharmaceuticals division drove the increase in sales, rising by nine percent to $11.2 billion, as its leading drugs such as heart failure treatment Entresto enjoyed a strong performance.
Novartis said it would appeal a US court ruling invalidating its patent for Entresto and noted no generic version of the medication is on the market in the United States.
Chief executive Vas Narasimhan said the strong performance of its medications plus its pipeline of future drugs gives Novartis confidence over the medium term and enables it to raise its 2023 outlook for a second time.
It now expects sales growth in the high single digits for 2023, compared to mid-single digits previously. Core operating income is now expected to post a low double-digit increase, compared to high single digit growth.
The company's "robust balance sheet and expected future growth" allows it to return $15 billion to shareholders "while maintaining the flexibility for continued strategic bolt-on acquisitions," Narasimhan said in a statement.
Novartis shares were up 3.1 percent in afternoon trading.
O.Hansen--CPN